Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
RESEARCH TOOLSreports
MBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.81 - $27.50
Previous CloseN/A
Volume52.29K
Average Volume (3M)335.20K
Market Cap
$306.50M
Enterprise Value$590.32M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)461.00K
Price to Earnings (P/E)―
Beta2.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding33,424,370
10 Day Avg. Volume405,229
30 Day Avg. Volume335,202
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.67Price Target Upside310.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
MBX Biosciences, Inc. News
PremiumCompany Announcements
MBX Biosciences Appoints Steve Hoerter to Board
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMBX's Phase 2 trial for hypoparathyroidism is highly anticipated and has a strong likelihood of demonstrating competitive response rates, which could significantly boost the company's valuation.
Market OpportunityThe U.S. total addressable market for hypoparathyroidism is over $15 billion, with MBX's lead candidate canvuparatide expected to capture significant sales due to its patient-friendly weekly dosing.
Bears Say
Side EffectsInstances of Grade 3 injection site reactions were observed, though 88% were mild or moderate and resolved within about 7 days.
Stock PerformanceStock traded down due to investor profit-taking and confusion around PD serum calcium levels in healthy volunteers.
---
Ownership Overview
Currently, No data available
---
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $27.50 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $306.50M.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Nov 07, 2024. The company reported -$2.78 earnings per share for the quarter, missing the consensus estimate of -$2.717 by -$0.063.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 33,424,370 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$2.78 in its last earnings report, missing expectations of -$2.717. Following the earnings report the stock price went up 2.066%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
---
MBX Biosciences, Inc. Stock Smart Score
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
---
MBX Stock 12 Month Forecast
Average Price Target
$37.67
▲(310.80% Upside)
Technical Analysis
Abeona Therapeutics
―
Solid Biosciences
―
iTeos Therapeutics
―
Olema Pharmaceuticals
―
enGene Holdings
―
---